PDF(Pubmed)
Abstract：
UNASSIGNED: Adverse events (AEs) of immune checkpoint inhibitors (ICIs) are frequent and mainly due to an overactivity of the immune system leading to excessive inflammatory responses (immune-related AE) that can affect any organ of the body. Beside the most frequent AEs, there are rare AEs whose diagnosis and treatment can be challenging. We report here a singular case of capillary leak syndrome (CLS) associated with chylothorax occurring in a patient who has been treated with adjuvant nivolumab (anti-PD1) for resected AJCC stage IIB primary melanoma.
UNASSIGNED: A 43-year-old woman was diagnosed with a nodular stage IIB melanoma of her left thigh, according to the AJCC 8th edition (T3bN0M0). The woman was treated with adjuvant nivolumab. She stopped the treatment after 4 infusions due to thrombopenia. Three months later, she developed facial and leg edema and ascites due to capillary leak syndrome. The CLS was associated with chylothorax and elevated vascular endothelial growth factor. The patient was initially treated with several pleural puncturing and steroids. CLS and chylothorax progressively decreased with intravenous immunoglobulins and fat-free diet without recurrence of melanoma at one-year follow-up.
UNASSIGNED: CLS is a rare and potentially life-threatening AE of ICIs such as anti-PD1. This AE may be associated with chylothorax probably related to lymphatic permeability induced by anti-PD1.
UNASSIGNED: A 43-year-old woman was diagnosed with a nodular stage IIB melanoma of her left thigh, according to the AJCC 8th edition (T3bN0M0). The woman was treated with adjuvant nivolumab. She stopped the treatment after 4 infusions due to thrombopenia. Three months later, she developed facial and leg edema and ascites due to capillary leak syndrome. The CLS was associated with chylothorax and elevated vascular endothelial growth factor. The patient was initially treated with several pleural puncturing and steroids. CLS and chylothorax progressively decreased with intravenous immunoglobulins and fat-free diet without recurrence of melanoma at one-year follow-up.
UNASSIGNED: CLS is a rare and potentially life-threatening AE of ICIs such as anti-PD1. This AE may be associated with chylothorax probably related to lymphatic permeability induced by anti-PD1.
摘要：
未经证实：免疫检查点抑制剂（ICIs）的不良事件（AE）是常见的，主要是由于免疫系统过度活跃，导致过度的炎症反应（免疫相关的AE），可以影响身体的任何器官。除了最常见的AE，有罕见的AE,其诊断和治疗可能具有挑战性.我们在此报告了一例与乳糜胸相关的毛细血管渗漏综合征（CLS）的单例病例，该患者已接受nivolumab辅助治疗（抗PD1）切除的AJCCIIB期原发性黑色素瘤。
未经证实：一名43岁的女性被诊断为左大腿结节性IIB期黑色素瘤，根据AJCC第8版(T3bN0M0)。该妇女用佐剂nivolumab治疗。由于血栓减少症，她在4次输液后停止了治疗。三个月后,由于毛细血管渗漏综合征，她出现了面部和腿部水肿和腹水。CLS与乳糜胸和血管内皮生长因子升高有关。患者最初接受了几次胸膜穿刺和类固醇治疗。在一年的随访中，静脉注射免疫球蛋白和无脂饮食使CLS和乳糜胸逐渐减少，而黑色素瘤没有复发。
未经证实：CLS是一种罕见且可能危及生命的ICIsAE，如抗PD1。这种AE可能与乳糜胸有关，可能与抗PD1诱导的淋巴通透性有关。
未经证实：一名43岁的女性被诊断为左大腿结节性IIB期黑色素瘤，根据AJCC第8版(T3bN0M0)。该妇女用佐剂nivolumab治疗。由于血栓减少症，她在4次输液后停止了治疗。三个月后,由于毛细血管渗漏综合征，她出现了面部和腿部水肿和腹水。CLS与乳糜胸和血管内皮生长因子升高有关。患者最初接受了几次胸膜穿刺和类固醇治疗。在一年的随访中，静脉注射免疫球蛋白和无脂饮食使CLS和乳糜胸逐渐减少，而黑色素瘤没有复发。
未经证实：CLS是一种罕见且可能危及生命的ICIsAE，如抗PD1。这种AE可能与乳糜胸有关，可能与抗PD1诱导的淋巴通透性有关。
